ライフサイエンスコーパス: risk of bleeding

1 rial fibrillation (score >/=3 indicates high risk of bleeding).

2 events but was associated with an increased risk of bleeding.

3 atients needing triple therapy increases the risk of bleeding.

4 zed ratio profile correlated poorly with the risk of bleeding.

5 ular events were accompanied by an increased risk of bleeding.

6 the polymorphism was associated with a lower risk of bleeding.

7 Rivaroxaban was associated with an increased risk of bleeding.

8 therapy can be associated with an increased risk of bleeding.

9 0.05 vs control each) without increasing the risk of bleeding.

10 92; P=0.02) was associated with an increased risk of bleeding.

11 ith concurrent bleeding or those with a high risk of bleeding.

12 but not continuing AC carries a significant risk of bleeding.

13 nd aspirin were associated with an increased risk of bleeding.

14 oncerns because of their potential increased risk of bleeding.

15 t cohort with a CHADS(2) score=2 and a lower-risk of bleeding.

16 ternative anticoagulants and their attendant risk of bleeding.

17 nting postoperative nausea without increased risk of bleeding.

18 ociated with a moderate relative increase in risk of bleeding.

19 embolic complications without increasing the risk of bleeding.

20 th atrial fibrillation (AF) but increase the risk of bleeding.

21 llows effective anticoagulation with minimal risk of bleeding.

22 schemic complications without increasing the risk of bleeding.

23 are-metal stent (BMS) for patients with high risk of bleeding.

24 l procedures are associated with significant risk of bleeding.

25 hat may reduce these events but also poses a risk of bleeding.

26 is associated with a significant increase in risk of bleeding.

27 res are performed percutaneously and carry a risk of bleeding.

28 ctivities retain efficacy while reducing the risk of bleeding.

29 hey inhibit arterial thrombosis with limited risk of bleeding.

30 no evidence that FFP transfusion alters the risk of bleeding.

31 a newer antiplatelet agent, can increase the risk of bleeding.

32 et all effective therapies also increase the risk of bleeding.

33 psis and may be associated with an increased risk of bleeding.

34 tor use must be weighed against an increased risk of bleeding.

35 rior cardiac surgery, along with a decreased risk of bleeding.

36 %, but that enoxaparin nearly quadrupled the risk of bleeding.

37 rove coronary patency without increasing the risk of bleeding.

38 th streptokinase, but there was an increased risk of bleeding.

39 eir narrow therapeutic window and associated risk of bleeding.

40 associated with improved outcomes or greater risk of bleeding.

41 k of thrombosis and stroke but increases the risk of bleeding.

42 o a reduced rate of VTE without an increased risk of bleeding.

43 of post-ERCP pancreatitis without increasing risk of bleeding.

44 ding and 217 procedures (40%) with increased risk of bleeding.

45 therapy can be associated with an increased risk of bleeding.

46 ving the lesion by thoracotomy to reduce the risk of bleeding.

47 aspect defined a new HCA subgroup at a high risk of bleeding.

48 myocardial infarction (MI) but increases the risk of bleeding.

49 and appeared to be safe with respect to the risk of bleeding.

50 >/= 10 mm Hg) and esophageal varices at high risk of bleeding.

51 ion-driven thrombosis without increasing the risk of bleeding.

52 o alterations in their efficacy and a higher risk of bleeding.

53 icoagulation in preventing stroke versus the risk of bleeding.

54 epsis in mouse models without increasing the risk of bleeding.

55 r 100 person-years, who are not at increased risk of bleeding.

56 efficacy to higher dose aspirin with reduced risk of bleeding.

57 ed VTE, without significantly increasing the risk of bleeding.

58 ually stopped at 3 months if there is a high risk of bleeding.

59 ulting from thrombosis, without an increased risk of bleeding.

60 terpatient dose-response variability and the risks of bleeding.

61 apy (DAPT), yet this treatment leads to high risks of bleeding.

62 rdless of indication) with standard care for risk of bleeding (19 trials on GIB).

63 associated with a transient increase in the risk of bleeding (30.6% of bleed windows vs 24.8% of fir

64 of ticagrelor was associated with a similar risk of bleeding according to the UDPB and E-CABG bleedi

65 n was associated with a dramatically reduced risk of bleeding across all categories of renal dysfunct

66 ng factors were associated with an increased risk of bleeding: acute hepatic failure, prolonged durat

67 cohort of patients was associated with lower risk of bleeding (adjusted odds ratio, 0.51; 95% confide

68 The risk of bleeding after percutaneous coronary interventio

69 atory drugs (NSAIDs) was not associated with risk of bleeding after polypectomy (OR=2.82, 95% C.I, 0.

70 enous thromboembolism unless there is a high risk of bleeding, although more data and better biomarke

71 Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surge

72 Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leu

73 g Board because of a significantly increased risk of bleeding among the participants receiving aspiri

74 41 cases: 324 procedures (60%) with standard risk of bleeding and 217 procedures (40%) with increased

75 pulation, characterized by both an increased risk of bleeding and a hypercoagulability state, as seen

76 g negative correlation between the predicted risk of bleeding and actual use of TRA in STEMI.

77 institution is associated with an increased risk of bleeding and adverse events but a trend toward l

78 er TIPS placement is associated with reduced risk of bleeding and ascites.

79 aft biopsies may be accompanied by a greater risk of bleeding and bowel injury, although no standardi

80 ecurrence, and secondarily influenced by the risk of bleeding and by patient preference.

81 ergoing surgical procedures, given increased risk of bleeding and cardiovascular and cerebrovascular

82 An increased risk of bleeding and cardiovascular events was evident w

83 nt stroke and did significantly increase the risk of bleeding and death.

84 ch as for cirrhosis is associated with a low risk of bleeding and death.

85 use of NSAIDs was associated with increased risk of bleeding and excess thrombotic events, even afte

86 s, their efficacy is limited by a heightened risk of bleeding and failure to affect vascular remodeli

87 as associated with a significantly increased risk of bleeding and probably would not result in a redu

88 Knowledge about risk of bleeding and short-term thrombotic risk resides

89 d with lower risk of reoperation but greater risk of bleeding and stroke.

90 g negative association between the predicted risk of bleeding and the use of TRA (P<0.001).

91 Strategies to reduce the daily risk of bleeding and thrombosis, and different threshold

92 ts admitted to the hospital are at increased risk of bleeding and thrombosis.

93 The risk of bleeding and thrombotic events during LVAD suppo

94 Minimizing the risk of bleeding and trauma to the kidney are important

95 sradial PCI (TRI) is associated with reduced risk of bleeding and vascular complications, as compared

96 nary intervention is associated with reduced risk of bleeding and vascular complications.

97 te anticoagulation puts them at considerable risk of bleeding and, with some anticoagulants, fetotoxi

98 er in the non-ICARD-certified group, but the risks of bleeding and vascular complications and the com

99 atological or oncological reasons who are at risk of bleeding), and chronic transfusion-dependent ane

100 romboprophylaxis because of rapid clearance, risk of bleeding, and central nervous system (CNS) toxic

101 t) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used in

102 The risk of bleeding appeared to differ according to smoking

103 e protection; a level beyond which increased risk of bleeding arises.

104 tion for ACT, there was a linear increase in risk of bleeding as the ACT approached 365 seconds (P=0.

105 rity of illness on the risk of death and the risk of bleeding associated with drotrecogin alfa (activ

106 ations in era II, and there was no increased risk of bleeding associated with the use of tPA.

107 The main disadvantage of these drugs is the risk of bleeding associated with their use.

108 The increased risk of bleeding associated with vitamin K antagonist (V

109 All patients had a greatly increased risk of bleeding at platelet counts of </=5 x 10(9)/L (o

110 of ischemia significantly exceeded the daily risk of bleeding beyond 30 days, supporting the use of i

111 ng medication use was associated with higher risk of bleeding but not stroke.

112 Critically ill patients who have a high risk of bleeding but require prolonged intermittent dial

113 with mild thrombocytopenia and an increased risk of bleeding, but its biological effect on megakaryo

114 r activity <10 U/dL were associated with the risk of bleeding, but only a BS >10 remained highly asso

115 d regimen tended to be associated with lower risk of bleeding compared with other regimens (RR 0.79 [

116 imilar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatmen

117 , dabigatran use was associated with a lower risk of bleeding compared with warfarin in men (P for in

118 igher mortality (P=0.002) and a 47.2% higher risk of bleeding complications (P=0.019).

119 ing surgical revascularization have a higher risk of bleeding complications and transfusion requireme

120 lar coagulation monitoring, but the inherent risk of bleeding complications associated with blocking

121 rocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker

122 to baseline bleeding risk; those at highest risk of bleeding complications gained the greatest benef

123 Anemia increases risk of bleeding complications in the critically ill.

124 An increased risk of bleeding complications was not observed.

125 lasminogen activators uniformly increase the risk of bleeding complications, especially intracranial

126 uture cardiovascular events as well as their risk of bleeding complications, patients may benefit fro

127 ntithrombotic strategy associated with a low risk of bleeding complications.

128 nts may be associated with unacceptably high risk of bleeding complications.

129 antiplatelet therapy without increasing the risk of bleeding complications.

130 ovenous hemodialysis (CVVHD) to minimize the risk of bleeding complications.

131 arin therapy and are potentially at a higher risk of bleeding complications.

132 Current data suggest that the increased risk of bleeding does not vary according to likelihood o

133 sepsis patients who are already at increased risk of bleeding due to a consumption coagulopathy.

134 otentially harmful side effects, such as the risk of bleeding due to heparin's anticoagulant activity

135 hrombus formation is limited by an increased risk of bleeding due to lysis of hemostatic clots that p

136 nerate recombinant APC variants with reduced risk of bleeding due to reduced anticoagulant activity,

137 ith tirofiban, but no unexpected incremental risk of bleeding due to tirofiban was observed among low

138 The risk of bleeding during antithrombotic therapy in patien

139 Moreover, the increased risk of bleeding episodes with clopidogrel and aspirin i

140 et agents has been associated with increased risk of bleeding (especially among the elderly and patie

141 reductions in heparin dosing may reduce the risk of bleeding even further.

142 cutaneous coronary intervention had a higher risk of bleeding events than their white counterparts.

143 lation has been associated with an increased risk of bleeding events, and despite the improvements li

144 prevented excess drug concentration and the risk of bleeding events.

145 conditional logistic regression, we compared risks of bleeding events at 1-month postdischarge betwee

146 The relative risk of bleeding for each BAS compared with no BAS was d

147 therapy with available agents outweighs the risk of bleeding for individual patients.

148 ny BAS was associated with a similarly lower risk of bleeding for men and women; however, the absolut

149 A patient's individual risk of bleeding from antithrombotic therapy should be a

150 c anomaly or variant that could increase the risk of bleeding from microelectrode mapping.

151 ary disease warranting DES but have a higher risk of bleeding from prolonged dual antiplatelet therap

152 progressive disease; and in patients at high risk of bleeding, full-dose LMWH for 7 days followed by

153 , patients treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0

154 ttenuates the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfron

155 GPI use was associated with increased risk of bleeding in both treatment arms.

156 th, MI, and ischemic stroke without a higher risk of bleeding in consecutive acute MI patients with a

157 whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown.

158 f sorafenib was associated with an increased risk of bleeding in HCC, this was primarily for lower-gr

159 lthough chronic kidney disease increases the risk of bleeding in nonoperative settings, the risk of p

160 Because of the substantial risk of bleeding in patients age > or =75 years, the num

161 Aspirin poses a risk of bleeding in patients undergoing surgery, but it

162 rction (NSTEMI) is associated with increased risk of bleeding in patients who undergo early CABG.

163 ults - tests that are not designed to assess risk of bleeding in patients without a history of bleedi

164 When comparing the risk of bleeding in single-arm phase 2 studies evaluatin

165 ile examining novel approaches to reduce the risk of bleeding in this rapidly expanding patient popul

166 latelet requirement and did not increase the risk of bleeding in thrombocytopenic neonates.

167 continue about prolonged ischemic times and risk of bleeding in various MIS settings.

168 Excess dosing was associated with increased risk of bleeding in women (OR 1.72, 95% CI 1.30 to 2.28)

169 Aspirin treatment increased the risk of bleeding in women (OR, 1.68; 95% CI, 1.13-2.52;

170 scular events can be offset by the increased risk of bleeding, including intracranial and gastrointes

171 all regimens that included VKA, whereas the risk of bleeding increased when aspirin (hazard ratio, 1

172 For warfarin-treated patients, the risk of bleeding increases as the INR rises, particularl

173 istration was associated with an increase in risk of bleeding, irrespective of baseline INR.

174 High risk of bleeding is immediately evident with TT after my

175 coronary events or thromboembolism, whereas risk of bleeding is increased significantly.

176 With attention to heparin dose the risk of bleeding is not a major concern with these agent

177 g as a function of a patient's preprocedural risk of bleeding is unknown.

178 zelle Bare Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE]; NCT01623180).

179 characteristics associated with an increased risk of bleeding, lower-risk infarction, less certain di

180 icient anticoagulant properties with reduced risk of bleeding may be possible through inhibition of f

181 Furthermore, the risk of bleeding may not be altered by the use of acid s

182 -6 days/wk) were associated with the highest risk of bleeding (multivariable HR, 2.32; 95% CI, 1.34-4

183 The risk of bleeding (n = 1202 events) was not significantly

184 8 vs. 74 min; p < 0.0001) but lower adjusted risk of bleeding (odds ratio [OR]: 0.62; 95% CI: 0.53 to

185 e risk of recurrent VTE off anticoagulation, risk of bleeding on anticoagulation, case fatality or al

186 s > or = 0.26 (base case 0.15), the relative risk of bleeding on BB is > or = 0.69 (base case 0.58),

187 The ICUR favored EVL unless the relative risk of bleeding on BB is < 0.46, the relative risk of b

188 ransplant recipients, including those at low risk of bleeding or high risk of thromboembolic complica

189 ransplants might be prevented by an elevated risk of bleeding or limited access to the allograft.

190 t significantly associated with an increased risk of bleeding or mortality.

191 ll tolerated, with no evidence for increased risk of bleeding or serious adverse events.

192 l dabigatran use significantly increases the risk of bleeding or thromboembolic complications compare

193 tio (INR) are routinely tested to assess the risk of bleeding or thrombosis and to monitor response t

194 rug-eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been prospectivel

195 elationship between plasma VWF level and the risk of bleeding or thrombosis.

196 bleeding should only be considered when the risk of bleeding outweighs the risk of thrombotic compli

197 Pediatric subjects were at higher risk of bleeding over a wide range of platelet counts, i

198 vs. 11% vs. 6%, p = 0.006), and had a higher risk of bleeding (p = 0001).

199 s with adjunctive GPIIb/IIIa inhibition, the risk of bleeding, particularly from the femoral vascular

200 administer during a code, and the increased risks of bleeding, particularly with ongoing chest compr

201 The risk of bleeding peaks early after HMII implantation.

202 ogical thromboprophylaxis but with a reduced risk of bleeding (relative risk, 0.41; 95% CI, 0.25-0.65

203 are currently identified by default, a high risk of bleeding remains a clinical issue.

204 Optimal thromboprophylaxis for patients at risk of bleeding remains uncertain.

205 ng was associated with an increased adjusted risk of bleeding requiring a return to the operating roo

206 I): 0.86 to 1.16]) but significantly greater risk of bleeding requiring hospitalization (adjusted HR:

207 Risk of bleeding (requiring hospitalization) or a compos

208 RR: 0.52, 95% CI: 0.35 to 0.76) but a higher risk of bleeding (RR: 2.80, 95% CI: 2.18 to 3.60).

209 ems to be limited to men, whereas the higher risk of bleeding seems to be limited to women.

210 over clopidogrel alone and carries a greater risk of bleeding than clopidogrel alone.

211 ath or thrombotic complications nor a higher risk of bleeding than that with placebo.

212 tranexamic acid was associated with a lower risk of bleeding than was placebo, without a higher risk

213 CrI, 0.15-0.62) were associated with a lower risk of bleeding than was the LMWH-vitamin K antagonist

214 Aspirin significantly increased the risk of bleeding to a similar degree among women and men

215 The risk of bleeding was also increased among patients who h

216 as an outpatient procedure, (2) whether the risk of bleeding was associated with either thrombocytop

217 The incremental risk of bleeding was greatest in the first year and simi

218 The risk of bleeding was greatest the first year.

219 In contrast, in children under 18, the risk of bleeding was higher in all treatment groups than

220 The overall risk of bleeding was lower with ximelagatran than warfar

221 The greatest risk of bleeding was noted within 2 weeks post-implantat

222 the patient with acute renal failure at high risk of bleeding, we have proposed regional heparinizati

223 t, as compared with clopidogrel, and similar risks of bleeding were observed.

224 cedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin unt

225 oagulation is often chosen if there is a low risk of bleeding, whereas anticoagulation is usually sto

226 There may be a slightly higher risk of bleeding, which may be related to the lack of br

227 d to inadequate clot formation and increased risk of bleeding, while thrombocythemia (platelet counts

228 lar bare-metal stent in patients with a high risk of bleeding who underwent PCI.

229 sk of bleeding on BB is < 0.46, the relative risk of bleeding with EVL is > 0.46, or the time horizon

230 = 0.69 (base case 0.58), or if the relative risk of bleeding with EVL is < 0.27 (base case 0.35).

231 In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel.

232 sted Cox regression analysis found increased risk of bleeding with NSAID treatment compared with no N

233 a inhibitor does not accentuate the relative risk of bleeding with prasugrel as compared with clopido

234 ior to VKAs with regard to efficacy, but the risk of bleeding with TSOACs remains controversial.

235 s can identify patients who are at increased risk of bleeding with warfarin and, consequently, those

236 mation of the benefit and underestimation of risk of bleeding with warfarin in clinical trials.

237 3%, 0-32.6; ptrend<0.0001) and had increased risks of bleeding with warfarin (sensitive responders ha

238 across the entire spectrum of preprocedural risk of bleeding, with or without exposure to IIb/IIIa i

239 tion and stent thrombosis, but decreases the risk of bleeding, with the magnitude of the reduction de